P1319: T AND B LYMPHOCYTES SUBSETS AFTER BNT162B2 ANTI-SARS-COV-2 M-RNA VACCINATION: A COMPARISON BETWEEN HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS AND HEALTHY CONTROLS.
Main Authors: | I. Attolico, F. Tarantini, C. P. Schifone, A. Mestice, G. De Tullio, C. Derosa, F. Carbone, A. Negri, P. Carluccio, M. Delia, F. Albano, A. M. V. Larocca, P. Stefanizzi, L. Vimercati, S. Tafuri, P. Musto |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-06-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000848140.30931.9f |
Similar Items
-
Medium-to-Long-Term Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine: A Retrospective Cohort Study
by: Francesco Paolo Bianchi, et al.
Published: (2022-03-01) -
Immunogenicity and safety of BNT162b2 mRNA COVID-19 vaccine in a subject affected by Shapiro’s syndrome: A case report
by: Lorenza Moscara, et al.
Published: (2022-11-01) -
Prospective, case-control study of serological response after two doses of BNT162b2 anti-SARS-CoV-2 mRNA vaccine in transfusion-dependent thalassemic patients
by: NICOLA SGHERZA, et al.
Published: (2022-06-01) -
Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
by: Rieke Reiter, et al.
Published: (2022-05-01) -
BNT162b2 mRNA COVID-19 Vaccine Effectiveness in the Prevention of SARS-CoV-2 Infection and Symptomatic Disease in Five-Month Follow-Up: A Retrospective Cohort Study
by: Francesco Paolo Bianchi, et al.
Published: (2021-10-01)